May-16-22 02:09PM | |
May-06-22 10:07AM | |
May-05-22 05:55PM | |
May-04-22 08:15AM | |
Apr-28-22 03:02PM | |
Apr-27-22 12:00PM | |
Apr-26-22 09:19AM | |
08:53AM | |
Apr-25-22 06:00PM | American City Business Journals |
05:57PM | |
04:30PM | |
Apr-22-22 08:30AM | |
Apr-20-22 12:54PM | |
09:17AM | |
Apr-18-22 05:25PM | American City Business Journals -23.05% |
11:30AM | |
10:39AM | |
09:48AM | |
09:32AM | |
Apr-14-22 04:42PM | |
04:30PM | |
Apr-05-22 05:50AM | |
Mar-30-22 11:30AM | |
Mar-16-22 12:32PM | |
Mar-15-22 10:38AM | |
Mar-14-22 05:43PM | American City Business Journals -60.87% |
04:27PM | Investor's Business Daily |
12:01PM | |
08:20AM | |
07:40AM | |
07:05AM | |
06:59AM | |
Mar-04-22 09:22AM | |
Mar-01-22 10:43AM | |
09:55AM | |
Feb-28-22 05:35PM | |
04:15PM | |
Feb-17-22 06:00PM | |
03:02PM | |
Feb-08-22 09:38AM | |
Feb-03-22 01:38PM | |
Jan-31-22 03:35PM | American City Business Journals |
Jan-21-22 01:38PM | |
Jan-20-22 09:38PM | |
Jan-19-22 01:38PM | |
Jan-05-22 09:00AM | |
Jan-03-22 09:38PM | |
Dec-31-21 08:56AM | |
Dec-15-21 09:10AM | |
Dec-14-21 11:31AM | |
Dec-13-21 03:59PM | |
09:00AM | |
Dec-11-21 12:38AM | |
Dec-03-21 07:51PM | |
Nov-30-21 08:00AM | |
Nov-19-21 11:52AM | |
08:20AM | |
Nov-15-21 08:30AM | |
Nov-12-21 07:00AM | |
Nov-09-21 08:15AM | |
Nov-05-21 04:11PM | |
11:00AM | |
Nov-04-21 10:32PM | |
05:35PM | |
04:15PM | |
Oct-26-21 06:00PM | |
Oct-25-21 04:01PM | |
Sep-22-21 11:09AM | |
Sep-21-21 11:02AM | |
09:00AM | |
Sep-13-21 11:47AM | |
Sep-02-21 12:03PM | |
Aug-06-21 12:31PM | |
Aug-05-21 09:31PM | |
05:45PM | |
04:15PM | |
Jul-29-21 03:05PM | |
Jul-27-21 06:00PM | |
Jul-26-21 05:09PM | |
Jul-19-21 09:00AM | |
Jun-07-21 08:30AM | |
Jun-04-21 10:46AM | |
May-27-21 06:36AM | |
May-20-21 11:00AM | |
May-18-21 08:00AM | |
May-10-21 03:09AM | |
May-07-21 03:30AM | |
May-06-21 05:45PM | |
04:15PM | |
Apr-29-21 12:34PM | |
Apr-27-21 06:00PM | |
Mar-27-21 11:31AM | |
Feb-26-21 09:09AM | |
07:20AM | |
03:11AM | |
01:01AM | |
Feb-25-21 05:10PM | |
03:15PM | |
Feb-18-21 05:30PM | |
Feb-17-21 04:19PM | Investor's Business Daily +13.36% |
|
|
|
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Zalevsky Jonathan | Chief R&D Officer | May 16 | Sale | 3.95 | 21,673 | 85,608 | 276,399 | May 17 09:40 PM | Wilson Mark Andrew | SVP & General Counsel | May 16 | Sale | 3.95 | 3,136 | 12,387 | 117,939 | May 17 09:38 PM | Thomsen Jillian B. | SVP & Chief Accounting Officer | May 16 | Sale | 3.95 | 5,841 | 23,072 | 170,427 | May 17 09:36 PM | ROBIN HOWARD W | President & CEO | May 16 | Sale | 3.95 | 36,529 | 144,290 | 620,941 | May 17 09:35 PM | NORTHCOTT JOHN | SVP & Chief Commercial Officer | May 16 | Sale | 3.95 | 4,592 | 18,138 | 223,210 | May 17 09:33 PM | Labrucherie Gil M | SVP, COO & CFO | May 16 | Sale | 3.95 | 17,448 | 68,920 | 312,905 | May 17 09:32 PM | Zalevsky Jonathan | Chief R&D Officer | Feb 16 | Sale | 10.95 | 10,912 | 119,486 | 274,122 | Feb 18 06:20 PM | Wilson Mark Andrew | SVP & General Counsel | Feb 16 | Sale | 10.95 | 3,661 | 40,088 | 121,075 | Feb 18 06:18 PM | Thomsen Jillian B. | SVP & Chief Accounting Officer | Feb 16 | Sale | 10.95 | 2,363 | 25,875 | 165,318 | Feb 18 06:18 PM | ROBIN HOWARD W | President & CEO | Feb 16 | Sale | 10.95 | 12,480 | 136,656 | 589,020 | Feb 18 06:16 PM | NORTHCOTT JOHN | SVP & Chief Commercial Officer | Feb 16 | Sale | 10.95 | 4,852 | 53,129 | 227,802 | Feb 18 06:15 PM | Labrucherie Gil M | SVP, COO & CFO | Feb 16 | Sale | 10.95 | 7,579 | 82,990 | 301,603 | Feb 18 06:14 PM | Labrucherie Gil M | SVP, COO & CFO | Nov 18 | Sale | 12.69 | 3,000 | 38,070 | 256,682 | Nov 18 06:06 PM | Labrucherie Gil M | SVP, COO & CFO | Nov 16 | Sale | 13.16 | 21,149 | 278,321 | 259,682 | Nov 18 06:06 PM | Zalevsky Jonathan | Chief R&D Officer | Nov 16 | Sale | 13.16 | 20,869 | 274,636 | 232,084 | Nov 17 06:11 PM | Wilson Mark Andrew | SVP & General Counsel | Nov 16 | Sale | 13.16 | 6,564 | 86,382 | 86,436 | Nov 17 06:09 PM | Thomsen Jillian B. | SVP & Chief Accounting Officer | Nov 16 | Sale | 13.16 | 6,741 | 88,712 | 145,981 | Nov 17 06:08 PM | NORTHCOTT JOHN | SVP & Chief Commercial Officer | Nov 16 | Sale | 13.16 | 6,061 | 79,763 | 194,854 | Nov 17 06:06 PM | ROBIN HOWARD W | President & CEO | Nov 16 | Sale | 13.16 | 42,773 | 562,893 | 475,450 | Nov 17 06:07 PM | GREER R SCOTT | Director | Nov 09 | Option Exercise | 12.80 | 12,500 | 160,000 | 293,374 | Nov 09 05:05 PM | Curet Myriam | Director | Sep 22 | Sale | 17.78 | 3,665 | 65,164 | 25,775 | Sep 24 06:14 PM | CHESS ROBERT | Director | Sep 22 | Sale | 17.94 | 4,600 | 82,524 | 279,873 | Sep 24 06:13 PM | Ajer Jeffrey Robert | Director | Sep 22 | Sale | 17.78 | 3,665 | 65,164 | 32,510 | Sep 24 06:12 PM | WHITFIELD ROY A | Director | Sep 16 | Option Exercise | 13.80 | 40,000 | 552,000 | 225,850 | Sep 17 06:44 PM | CHESS ROBERT | Director | Sep 09 | Option Exercise | 13.80 | 10,279 | 141,850 | 284,552 | Sep 10 06:03 PM | CHESS ROBERT | Director | Sep 09 | Sale | 16.02 | 10,279 | 164,670 | 274,273 | Sep 10 06:03 PM | CHESS ROBERT | Director | Sep 08 | Option Exercise | 13.80 | 8,000 | 110,400 | 282,273 | Sep 10 06:03 PM | CHESS ROBERT | Director | Sep 08 | Sale | 16.00 | 8,000 | 128,000 | 274,273 | Sep 10 06:03 PM | GREER R SCOTT | Director | Aug 31 | Option Exercise | 12.70 | 45,000 | 571,500 | 270,674 | Aug 31 06:26 PM | Labrucherie Gil M | SVP, COO & CFO | Aug 17 | Sale | 13.56 | 3,000 | 40,680 | 240,231 | Aug 18 06:58 PM | Zalevsky Jonathan | Chief R&D Officer | Aug 16 | Sale | 13.83 | 7,662 | 105,965 | 212,803 | Aug 18 07:04 PM | Wilson Mark Andrew | SVP & General Counsel | Aug 16 | Sale | 13.83 | 1,910 | 26,415 | 72,900 | Aug 18 07:02 PM | Thomsen Jillian B. | SVP & Chief Accounting Officer | Aug 16 | Sale | 13.83 | 13,339 | 184,478 | 137,822 | Aug 18 07:00 PM | ROBIN HOWARD W | President & CEO | Aug 16 | Sale | 13.83 | 11,515 | 159,252 | 424,123 | Aug 18 07:01 PM | NORTHCOTT JOHN | SVP & Chief Commercial Officer | Aug 16 | Sale | 13.83 | 6,192 | 85,635 | 200,915 | Aug 18 06:59 PM | Labrucherie Gil M | SVP, COO & CFO | Aug 16 | Sale | 13.83 | 7,867 | 108,801 | 243,231 | Aug 18 06:58 PM | CHESS ROBERT | Director | Jul 22 | Option Exercise | 13.80 | 91 | 1,256 | 280,664 | Jul 22 07:13 PM | CHESS ROBERT | Director | Jul 22 | Sale | 16.80 | 91 | 1,529 | 280,573 | Jul 22 07:13 PM | CHESS ROBERT | Director | Jul 21 | Option Exercise | 13.80 | 3,524 | 48,631 | 284,097 | Jul 22 07:13 PM | CHESS ROBERT | Director | Jul 21 | Sale | 16.81 | 3,524 | 59,238 | 280,573 | Jul 22 07:13 PM | CHESS ROBERT | Director | Jul 20 | Option Exercise | 13.80 | 2,106 | 29,063 | 282,679 | Jul 22 07:13 PM | CHESS ROBERT | Director | Jul 20 | Sale | 16.80 | 2,106 | 35,381 | 280,573 | Jul 22 07:13 PM |
|